Literature DB >> 16825499

Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.

Ute Modlich1, Jens Bohne, Manfred Schmidt, Christof von Kalle, Sabine Knöss, Axel Schambach, Christopher Baum.   

Abstract

Retroviral vectors with long terminal repeats (LTRs), which contain strong enhancer/promoter sequences at both ends of their genome, are widely used for stable gene transfer into hematopoietic cells. However, recent clinical data and mouse models point to insertional activation of cellular proto-oncogenes as a dose-limiting side effect of retroviral gene delivery that potentially induces leukemia. Self-inactivating (SIN) retroviral vectors do not contain the terminal repetition of the enhancer/promoter, theoretically attenuating the interaction with neighboring cellular genes. With a new assay based on in vitro expansion of primary murine hematopoietic cells and selection in limiting dilution, we showed that SIN vectors using a strong internal retroviral enhancer/promoter may also transform cells by insertional mutagenesis. Most transformed clones, including those obtained after dose escalation of SIN vectors, showed insertions upstream of the third exon of Evi1 and in reverse orientation to its transcriptional orientation. Normalizing for the vector copy number, we found the transforming capacity of SIN vectors to be significantly reduced when compared with corresponding LTR vectors. Additional modifications of SIN vectors may further increase safety. Improved cell-culture assays will likely play an important role in the evaluation of insertional mutagenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825499      PMCID: PMC1895590          DOI: 10.1182/blood-2005-08-024976

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  HIV-1-derived lentiviral vectors.

Authors:  L E Ailles; L Naldini
Journal:  Curr Top Microbiol Immunol       Date:  2002       Impact factor: 4.291

Review 2.  Progress and problems with the use of viral vectors for gene therapy.

Authors:  Clare E Thomas; Anja Ehrhardt; Mark A Kay
Journal:  Nat Rev Genet       Date:  2003-05       Impact factor: 53.242

3.  Polyclonal long-term repopulating stem cell clones in a primate model.

Authors:  Manfred Schmidt; Philipp Zickler; Gesa Hoffmann; Sebastian Haas; Manuela Wissler; Arne Muessig; John F Tisdale; Ken Kuramoto; Robert G Andrews; Tong Wu; Hans-Peter Kiem; Cynthia E Dunbar; Christof von Kalle
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

4.  High-level ectopic HOXB4 expression confers a profound in vivo competitive growth advantage on human cord blood CD34+ cells, but impairs lymphomyeloid differentiation.

Authors:  Bernhard Schiedlmeier; Hannes Klump; Elke Will; Gökhan Arman-Kalcek; Zhixiong Li; Zheng Wang; Andreas Rimek; Jutta Friel; Christopher Baum; Wolfram Ostertag
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

Review 5.  Retroviral insertional mutagenesis: tagging cancer pathways.

Authors:  Harald Mikkers; Anton Berns
Journal:  Adv Cancer Res       Date:  2003       Impact factor: 6.242

6.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.

Authors:  Salima Hacein-Bey-Abina; Françoise Le Deist; Frédérique Carlier; Cécile Bouneaud; Christophe Hue; Jean-Pierre De Villartay; Adrian J Thrasher; Nicolas Wulffraat; Ricardo Sorensen; Sophie Dupuis-Girod; Alain Fischer; E Graham Davies; Wietse Kuis; Lilly Leiva; Marina Cavazzana-Calvo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

7.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

Review 8.  Side effects of retroviral gene transfer into hematopoietic stem cells.

Authors:  Christopher Baum; Jochen Düllmann; Zhixiong Li; Boris Fehse; Johann Meyer; David A Williams; Christof von Kalle
Journal:  Blood       Date:  2003-01-02       Impact factor: 22.113

9.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728

10.  Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors:  Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

View more
  147 in total

1.  A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.

Authors:  Sheng Zhou; Disha Mody; Suk See DeRavin; Julia Hauer; Taihe Lu; Zhijun Ma; Salima Hacein-Bey Abina; John T Gray; Michael R Greene; Marina Cavazzana-Calvo; Harry L Malech; Brian P Sorrentino
Journal:  Blood       Date:  2010-05-10       Impact factor: 22.113

Review 2.  Safe harbours for the integration of new DNA in the human genome.

Authors:  Michel Sadelain; Eirini P Papapetrou; Frederic D Bushman
Journal:  Nat Rev Cancer       Date:  2011-12-01       Impact factor: 60.716

Review 3.  Hematopoietic stem cell engineering at a crossroads.

Authors:  Isabelle Rivière; Cynthia E Dunbar; Michel Sadelain
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

4.  Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors.

Authors:  Wenqin Xu; Jill L Russ; Maribeth V Eiden
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

5.  Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing.

Authors:  Anna Paruzynski; Anne Arens; Richard Gabriel; Cynthia C Bartholomae; Simone Scholz; Wei Wang; Stephan Wolf; Hanno Glimm; Manfred Schmidt; Christof von Kalle
Journal:  Nat Protoc       Date:  2010-07-08       Impact factor: 13.491

6.  Assessing the risk of T-cell malignancies in mouse models of SCID-X1.

Authors:  Brian Sorrentino
Journal:  Mol Ther       Date:  2010-05       Impact factor: 11.454

7.  Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways.

Authors:  Olga S Kustikova; Hartmut Geiger; Zhixiong Li; Martijn H Brugman; Stuart M Chambers; Chad A Shaw; Karin Pike-Overzet; Dick de Ridder; Frank J T Staal; Gottfried von Keudell; Kerstin Cornils; Kalpana Jekumar Nattamai; Ute Modlich; Gerard Wagemaker; Margaret A Goodell; Boris Fehse; Christopher Baum
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

8.  An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.

Authors:  Byoung Y Ryu; Marguerite V Evans-Galea; John T Gray; David M Bodine; Derek A Persons; Arthur W Nienhuis
Journal:  Blood       Date:  2007-11-08       Impact factor: 22.113

9.  Efficiency and safety of O⁶-methylguanine DNA methyltransferase (MGMT(P140K))-mediated in vivo selection in a humanized mouse model.

Authors:  Ruhi Phaltane; Reinhard Haemmerle; Michael Rothe; Ute Modlich; Thomas Moritz
Journal:  Hum Gene Ther       Date:  2014-01-07       Impact factor: 5.695

10.  Comprehensive genomic access to vector integration in clinical gene therapy.

Authors:  Richard Gabriel; Ralph Eckenberg; Anna Paruzynski; Cynthia C Bartholomae; Ali Nowrouzi; Anne Arens; Steven J Howe; Alessandra Recchia; Claudia Cattoglio; Wei Wang; Katrin Faber; Kerstin Schwarzwaelder; Romy Kirsten; Annette Deichmann; Claudia R Ball; Kamaljit S Balaggan; Rafael J Yáñez-Muñoz; Robin R Ali; H Bobby Gaspar; Luca Biasco; Alessandro Aiuti; Daniela Cesana; Eugenio Montini; Luigi Naldini; Odile Cohen-Haguenauer; Fulvio Mavilio; Adrian J Thrasher; Hanno Glimm; Christof von Kalle; William Saurin; Manfred Schmidt
Journal:  Nat Med       Date:  2009-11-22       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.